Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Febico Biomedical Corp.
- Target Recruit Count
- 120
- Registration Number
- NCT06478719
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
News
No news found